Physician profile
Mark S Abel
NPI 1225180961
$5,566.83
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $1,108 · 2021: $1,646 · 2022: $1,205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $988.20 | 2019-2022 | |
| Novo Nordisk INC | $939.17 | 2019-2022 | |
| Amgen INC. | $920.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $322.21 | 2019-2022 | |
| Pfizer INC. | $261.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $214.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $202.03 | 2019-2022 | |
| Abbvie INC. | $199.87 | 2019-2022 | |
| Lilly USA, LLC | $182.04 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $172.06 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.69 | 2019-2021 | |
| Amarin Pharma, INC. | $102.73 | 2019-2022 | |
| Esperion Therapeutics, INC. | $100.81 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.16 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $78.35 | 2021-2022 | |
| Eisai INC. | $60.64 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $56.50 | 2021 | |
| Nestle Healthcare Nutrition INC. | $47.29 | 2021 | |
| Allergan, INC. | $35.10 | 2019-2020 | |
| Abbott Laboratories | $31.40 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $22.09 | 2022 | |
| Lifescan, INC. | $21.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.25 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.97 | 2022 | |
| Sanofi Pasteur INC. | $16.86 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.51 | 2021 | |
| Grifols USA, LLC | $14.48 | 2020 | |
| Astellas Pharma US INC | $13.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.48 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.46 | 2021 | |
| Boston Scientific Corporation | $12.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.03 | 2022 | |
| Cequr Corporation | $10.80 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.